In February 2017, Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. Cannabics has become one of the few companies in the world conducting Cannabinoid scientific research, developing Cannabinoid-based treatments, and performing clinical studies for cannabis medicines. The Company’s principal product is Cannabics Oil Capsule that provides a safe, effective, and reliable administration of cannabis. Through its joint venture ownership in MIDS Medical Ltd., Zenosense, Inc. (OTCQB: ZENO) is developing a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, “MIDS Cardiac", used at the Point of Care replacing slow and expensive laboratory testing. Management believes that its MIDS technology can be applied across a very wide spectrum of medical tests. Aurora Cannabis Inc. (OTCQB: ACBFF) recently commended Canada's federal government on its legislative framework for the legalization of adult consumer use of cannabis. The Company operates a 55,200-square foot, state-of-the-art cannabis production facility in Mountain View County, Alberta, is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport. Innovativ Media Group, Inc. (OTCBB: INMG), has acquired the media assets of Canna TV OÜ and will be launching a new online, ad supported platform and channel CannaNet.TV http://cannanet.tv/ which will stream curated and original entertainment, informational and educational video content related to the Cannabis and CBD culture and industries. The Company has posted 6 Quarters of successive earnings since acquiring the Innovativ Media entertainment assets in mid-2015.
 
Get this must read Cannabis report with no obligation here- http://tradersnewssource.com/cannabis-report/
 
 
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
 
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
 
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC editor Mark Roberts, (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
 

CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more CNBX Pharmaceuticals (QB) Charts.
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more CNBX Pharmaceuticals (QB) Charts.